Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US

Bibliographic Details
Title: Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US
Authors: Rafael Fonseca, May Hagiwara, Sumeet Panjabi, Emre Yucel, Jacqueline Buchanan, Thomas Delea
Source: Blood Cancer Journal, Vol 11, Iss 2, Pp 1-11 (2021)
Publisher Information: Nature Publishing Group, 2021.
Publication Year: 2021
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Abstract Effects of disease progression on healthcare resource utilization (HRU) and costs among multiple myeloma (MM) patients with ≥1 line of therapy (LOT) who received their first stem cell transplant (SCT) within 1 year of initial MM diagnosis were estimated using a large US claims database. Disease progression was defined as advancement to the next LOT, bone metastasis, hypercalcemia, soft tissue plasmacytoma, skeletal related events, acute kidney disease, or death within 12 months of LOT initiation. Annual HRU and costs in the first three LOTs (L1–L3) were compared for patients with versus without disease progression using inverse probability of treatment weighting to adjust for differences between groups in baseline characteristics. In all LOTs, mean annual hospitalizations and healthcare costs were greater for patients with versus without progression. Total incremental annual costs among patients with versus without progression in L1–L3 were $18,359, $87,055, and $71,917, respectively, among LOTs initiated between 2006 and 2018. In LOTs initiated between 2013 and 2018, the figures were $46,024, $100,329, and $101,942 in L1–L3, respectively. The economic burden of disease progression is substantial in this population of MM patients who underwent SCT and received systemic anti-myeloma therapy.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2044-5385
Relation: https://doaj.org/toc/2044-5385
DOI: 10.1038/s41408-021-00431-5
Access URL: https://doaj.org/article/ddc0f98d0a31440b99138b5c61872540
Accession Number: edsdoj.0f98d0a31440b99138b5c61872540
Database: Directory of Open Access Journals
More Details
ISSN:20445385
DOI:10.1038/s41408-021-00431-5
Published in:Blood Cancer Journal
Language:English